Vivo Capital VIII, LLC - 15 Dec 2023 Form 4 Insider Report for IMPEL PHARMACEUTICALS INC

Role: 10%+ Owner
Signature: Vivo Capital VIII, LLC, By: /s/ Frank Kung, Managing Member
Issuer symbol: N/A
Transactions as of: 15 Dec 2023
Net transactions value: -$74,131
Form type: 4
Filing time: 19 Dec 2023, 18:00:01 UTC
Previous filing: 22 Nov 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMPL	Common Stock	Sale	$25,501	-87,934	-3.5%	$0.2900	2,447,181	15 Dec 2023	By: Vivo Capital Fund VIII, L.P.	F1, F3
transaction	IMPL	Common Stock	Sale	$3,499	-12,066	-3.5%	$0.2900	337,608	15 Dec 2023	By: Vivo Capital Surplus Fund VIII, L.P.	F2, F3
transaction	IMPL	Common Stock	Sale	$22,993	-209,029	-8.5%	$0.1100^*	2,238,152	18 Dec 2023	By: Vivo Capital Fund VIII, L.P.	F1, F4
transaction	IMPL	Common Stock	Sale	$3,155	-28,682	-8.5%	$0.1100^*	308,926	18 Dec 2023	By: Vivo Capital Surplus Fund VIII, L.P.	F2, F4
transaction	IMPL	Common Stock	Sale	$16,693	-208,657	-9.3%	$0.0800^*	2,029,495	19 Dec 2023	By: Vivo Capital Fund VIII, L.P.	F1, F5
transaction	IMPL	Common Stock	Sale	$2,291	-28,632	-9.3%	$0.0800^*	280,294	19 Dec 2023	By: Vivo Capital Surplus Fund VIII, L.P.	F2, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Vivo Capital VIII, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	The shares are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F2	The shares are held of record by Vivo Capital Surplus Fund VIII, L.P. Capital VIII, LLC is the General Partner of Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F3	The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.44 to $0.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.
F4	The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.30 to $0.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
F5	The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.10 to $0.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.